Tag: AMG 334
January 22, 2018
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients
Novartis (VTX:NOVN) announced positive results from the Phase IIIb LIBERTY study assessing the efficacy and safety of erenumab (AMG 334)...
November 17, 2016